BG98522A - Пептиди, индуциращи цитотоксичен т-лимфоцитен отговор на вируса на хепатит в - Google Patents

Пептиди, индуциращи цитотоксичен т-лимфоцитен отговор на вируса на хепатит в

Info

Publication number
BG98522A
BG98522A BG98522A BG9852294A BG98522A BG 98522 A BG98522 A BG 98522A BG 98522 A BG98522 A BG 98522A BG 9852294 A BG9852294 A BG 9852294A BG 98522 A BG98522 A BG 98522A
Authority
BG
Bulgaria
Prior art keywords
hbv
hepatitis
peptides
virus
methods
Prior art date
Application number
BG98522A
Other languages
Bulgarian (bg)
English (en)
Inventor
Francis Chisari
Carlo Ferrari
Amalia Penna
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of BG98522A publication Critical patent/BG98522A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BG98522A 1991-08-26 1994-02-22 Пептиди, индуциращи цитотоксичен т-лимфоцитен отговор на вируса на хепатит в BG98522A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74954091A 1991-08-26 1991-08-26
PCT/US1992/007213 WO1993003753A1 (en) 1991-08-26 1992-08-26 Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus

Publications (1)

Publication Number Publication Date
BG98522A true BG98522A (bg) 1995-05-31

Family

ID=25014174

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98522A BG98522A (bg) 1991-08-26 1994-02-22 Пептиди, индуциращи цитотоксичен т-лимфоцитен отговор на вируса на хепатит в

Country Status (19)

Country Link
EP (1) EP0534618B1 (de)
JP (3) JP3566284B2 (de)
AT (1) ATE320444T1 (de)
AU (1) AU679901B2 (de)
BG (1) BG98522A (de)
CA (1) CA2115927C (de)
CZ (1) CZ42894A3 (de)
DE (1) DE69233607T2 (de)
DK (1) DK0534618T3 (de)
ES (1) ES2262132T3 (de)
FI (1) FI940919A7 (de)
HU (1) HUT67529A (de)
IL (1) IL102963A0 (de)
NO (1) NO940661L (de)
NZ (2) NZ244102A (de)
OA (1) OA09889A (de)
PT (1) PT534618E (de)
WO (1) WO1993003753A1 (de)
ZA (1) ZA926440B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
WO1999036434A1 (en) * 1998-01-19 1999-07-22 Mogam Biotechnology Research Institute Liposomes comprising peptide antigens derived from x protein of hepatitis b virus
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
GB0328753D0 (en) * 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CA2955604A1 (en) * 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
SG11201811442UA (en) 2016-06-20 2019-01-30 Isa Pharmaceuticals B V Formulation of a peptide vaccine
CN113939527B (zh) * 2019-01-11 2025-10-28 新加坡科技研究局 Hla-a*11:01限制性乙型肝炎病毒(hbv)肽用于鉴别hbv特异性cd8+ t细胞的用途
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939900A (de) * 1972-08-25 1974-04-13
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Also Published As

Publication number Publication date
JP2003267997A (ja) 2003-09-25
EP0534618B1 (de) 2006-03-15
EP0534618A2 (de) 1993-03-31
FI940919A0 (fi) 1994-02-25
WO1993003753A1 (en) 1993-03-04
ZA926440B (en) 1993-06-07
IL102963A0 (en) 1993-01-31
NZ244102A (en) 1996-12-20
CA2115927C (en) 2009-04-21
ES2262132T3 (es) 2006-11-16
AU679901B2 (en) 1997-07-17
JP2003300999A (ja) 2003-10-21
NZ270625A (en) 1996-12-20
ATE320444T1 (de) 2006-04-15
FI940919L (fi) 1994-04-25
AU2540892A (en) 1993-03-16
DE69233607T2 (de) 2006-11-30
CZ42894A3 (en) 1995-02-15
JPH06510050A (ja) 1994-11-10
CA2115927A1 (en) 1993-03-04
JP3566284B2 (ja) 2004-09-15
JP3694299B2 (ja) 2005-09-14
JP3694300B2 (ja) 2005-09-14
HUT67529A (en) 1995-04-28
FI940919A7 (fi) 1994-04-25
DK0534618T3 (da) 2006-07-24
NO940661L (no) 1994-04-19
OA09889A (en) 1994-09-15
PT534618E (pt) 2006-08-31
DE69233607D1 (de) 2006-05-11
HU9400582D0 (en) 1994-07-28
NO940661D0 (no) 1994-02-25
EP0534618A3 (en) 1993-06-30

Similar Documents

Publication Publication Date Title
BG98522A (bg) Пептиди, индуциращи цитотоксичен т-лимфоцитен отговор на вируса на хепатит в
Dietzschold et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.
Dienstag et al. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen
EP0726758A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
Pol et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine
Tollis et al. Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies
Palmović et al. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia
Wiedermann et al. Multicentre dose range study of a yeast-derived hepatitis B vaccine
Willey et al. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection
Ishihara et al. Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease
Zage et al. Epidemiology, virology, transmission, clinical manifestation and vaccine for hepatitis virus B: a review
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
Emir et al. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer
Hilleman Immunologic prevention of human hepatitis
Coutinho Hepatitis B vaccination
Mannhalter et al. Immunization of Chimpanzees with Recombinant gp160, but not Infection with Human Immunodeficiency Virus Type 1, Induces Envelope-Specific Thl Memory Cells
Deinhardt Strategies in the Prevention of Infections by Oncogenic Viruses
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
Kalayanarooj et al. Protective antibody after a'one dollar'hepatitis B vaccine
Weibel titis B surface antigen (HBsAg) obtained by plasmaphoresis (3). Additional markers (shown in Figure 1) of human hepatitis B infec
KRUGMAN The development of a vaccine against hepatitis B
Park et al. Heat-inactivated and Aggregated HBsAg as a New Type of Vaccine Against Hepatitis B
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus